Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (9849)	5/8/1999 2:12:00 PM
From: RXGOLF	Read Replies (1) \| Respond to of 17367

While on the subject of M.Murphy: I was just looking at a "teaser" I received in the mail a few days ago from the Editor of Technology Investing, M. Murphy. It says "New drug wins fight against meningitis: stock on the road to $45 from $4. Bacterial meningitis is a vicious killer of children, and Xoma's winning the war. Xoma has developed a protein that make the body immune to meningitis bacteria. In a recent test on 25 children, 24 survived, impressing the FDA so much, the agency ordered acceleration of the trials. A spin-off drug will find widespread use against bacteria that have become resistant to antibiotics. At TECHNOLOGY INVESTING we have a target of $45 within 12 months. But don't you buy yet--you'll see why in your special report!" Please remember this is a quote, and do your own DD, Good investing, Greg